“We thank Roel for his immense contribution in building M Ventures as a leading corporate venture fund and wish him all the best for his future endeavors,” said Isabel De Paoli, chief strategy officer at Merck KGaA. “M Ventures is an important strategic lever in our ambitions to push the edge of science and technology. We are glad to be able to fill the role with an internal talent and experienced investor. Jasper Bos has been with M Ventures since 2009 and is crucial to the success of the healthcare fund, which he will continue to lead.”
Bos joined Merck KGaA’s previous biopharma fund of M Ventures in 2009 and transitioned to VP leading the healthcare team for the current fund in 2016. At M Ventures, Bos supported (among others) the early successful investments and exits in ObsEva, EpiTherapeutics (sale to Gilead), and was an initiator of Prexton Therapeutics, which was acquired early 2018 by Lundbeck for close to US$ 1.1 billion.
M Ventures has the mandate to invest into the four sector-focused areas: Healthcare, Life Science, Performance Materials and New Businesses. The total volume of M Ventures is €300 million in an evergreen structure. Recent investments of M Ventures include, among numerous others, Artios, Galecto, Ribometrix, CLEARink Displays, DNAScript, Mosa Meat, and Akili Interactive.